**Appendix Table E39. Results from studies assessing the ability of VerifyNow to predict other clinical events in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,year**  **UID**  **Country**  **Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)**  **[statistical test]** | **Adjusted?**  **[YES/NO/NR]**  **If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Kim, 2011{Kim, 2011 5 /id}  21786434  South Korea  CiLostazol administration before pErcutaneous coronAry intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial) | Clopidogrel+aspirin | VerifyNow | Target-lesion revascularization |  | 6 months | Clopidogrel resistance |  | 2/37 (5%) |  |  | NS vs. next row (chi-square statistics or Fisher ’s exact test) |  |  |  |
|  |  |  |  |  |  | Normal response |  | 1/73 (1%) |  |  |  |  |  |  |
| Marcucci, 2009{Marcucci, 2009 144 /id}  19118249  Italy  NR | clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100-325 mg MD | VerifyNow | Target-lesion revascularization | by repeat PCI or CABG | 12 months | high residual platelet reactivity (PRU≥240) | Target-lesion revascularization | 16 (7.3) | HR=1.48 | 0.78–2.78 | P=0.225  (RPR vs no RPR) | NO | NR |  |
|  |  |  |  |  |  | No residual platelet reactivity (PRU<240) |  | 24 (5.2) |  |  |  |  |  |  |
| Patti, 2011{Patti, 2011 22 /id}  21256470  Italy  Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty (ARMYDA)–Bleeding Study (ARMYDA-BLEEDS) | Clopidogrel + aspirin | VerifyNow | 30-day incidence of major TIMI bleeding or signiﬁcant entry-site complications (hematoma > 10 cm in diameter, pseudoaneurysm, or arteriovenous ﬁstula) | NR | Within 1 mo | PRU Q1 (highest inhibition) (n=77) | Yes bleeding | 10.1% | OR, 4.5  (NR whether this is vs. Q4 or vs. Q2-4) | 1.9-25.9 | For incidence, 0.043 vs. next row (Fisher’s exact or chi-square)  For OR, 0.01 | NR for incidence  YES for OR: age, sex, BMI, DM, stable angina vs ACS, chronic renal failure, hemoglobin levels, previous TIA or stroke, previous major bleeding, use of bivalirudin vs. unfractionated heparin, and use of glycoprotein IIb/IIIa inhibitors | NR | NONE |
|  |  |  |  |  |  | PRUQ4 (n=79) |  | 1.3% | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | PRU Q3 (n=77) |  | 1.4% | NR | NR | 0.05 vs. first row (Fisher’s exact or chi-square) | NR | NR |  |
|  |  |  |  |  |  | PRU Q2 (n=77) |  | 6.3% | NR | NR | NR | NR | NR |  |
| Park, 2011 {Park, 2011 1 /id} 22152948  Korea  NR | clopidogrel LD 300 or 600 mg>=12h before PCI, MD 75mg/day  aspirin LD 200mg, MD 100-200 mg/day | VerifyNow | revascularization | revascularization | 2-year | HTPR (PRU >235 and/or a % inhibition <15%) | revascularization | high 78/1660 (4.3) | HR=0.94 | 0.67-1.31 | 0.71  comparing with normal  cox proportional model | NR | NR |  |
|  |  |  |  |  |  |  |  | normal  62/1189  (5.1) |  |  |  |  |  |  |
| Park, 2011{Park, 2011 18181 /id}  21880289  Korea  CROSS-VERIFY | clopidogrel LD 300 or 600 mg, MD 75mg/day; aspirin MD 100 mg/day | VerifyNow | Target vessel revascularization | any repeat percutaneous  intervention or surgical bypass of any segment of the target  vessel | 1 year | high OPR (HOPR) ≥235 PRU  n=407 | MACE | 10 (2.6%) | NR | NR | P=0.861  (HOPR vs no HOPR)  Log rank test | NR | NR |  |
|  |  |  |  |  |  | No HOPR <235 PRU  n=402 |  | 1 (0.3%) |  |  |  |  |  |  |
| Mangiacapra, 2012{Mangiacapra, 2012 18179 /id}  22440493  Italy & Belgium  ARMYDA-PROVE | Clopidogrel LD: 600 mg loading dose ≥6 h before PCI or 75 mg/d x 5 days  Clopidogrel MD: 75 mg/d from 4 weeks to 12 months  Aspirin 80-100 mg/day | VerifyNow | Target vessel revascularization | Target vessel revascularization | 30 days | Low PR (PRU ≤178)  n = 248 | Target vessel revascularization | 1 (0.4%) | NR | NR | P for trend =0.041 | No | NR |  |
|  |  |  |  |  |  | Normal PR (PRU between ≥179 and ≤238)  n = 244 |  | 0 (0%) | OR=0.15(calculated) | 0.009-2.71 | normal vs other |  |  |  |
|  |  |  |  |  |  | High PR (PRU ≥239)  n = 240 |  | 5 (2.1%) |  |  |  |  |  |  |
|  |  |  | Hematoma>10 cms | Hematoma>10 cms | 30 days | Low PR (PRU ≤178)  n = 248 | Hematoma>10 cms | 19 (7.7%) | NR | NR | P for trend <0.001 | No | NR |  |
|  |  |  |  |  |  | Normal PR (PRU between ≥179 and ≤238)  n = 244 |  | 6 (2.5%) |  |  |  |  |  |  |
|  |  |  |  |  |  | High PR (PRU ≥239)  n = 240 |  | 3 (1.3%) |  |  |  |  |  |  |